The associations of GLP1 receptor agonist versus DPP4 inhibitor initiation with all-cause dementia risk were not statistically significant in those with atherosclerotic cardiovascular disease (HR [95% CI]: 0.89 [0.75–1.05]), and in those with renal insufficiency (HR [95% CI]: 0.87 [0.74–1.03]). This evidence concerns the gene GLP1R and Renal insufficiency.